Forma Therapeutics, Inc.

Neurogen Corporation

Pfizer Corporation

Ligand Pharmaceuticals, Inc.

Novo Nordisk Healthcare Ag

Novartis International Pharmaceutical, Ltd.

George P Luke

Matthew W Martin

Shawn E R Schiller

Kenneth W Bair

David S Millan

Adam Charles Talbot

Torsten Herbertz

Katherine J Kayser-Bricker

Goss S Kauffman

George D Maynard

Jun Yuan

Kevin S Currie

Kyungae Lee

Manuka Ghosh

Mark Joseph Tebbe

Alan J Hutchison

Scott A Mitchell

Linda M Gustavson

Linghong Xie

Guiying Li

Pratik Sheth

Pamela Ann Albaugh

Bertrand Leo Chenard

Guolin Cai

Spiros Liras

Robert Wenslow

Martin Patrick Allen

Nian Liu

Jun Huang

Daniel Yohannes

Lawrence Albert Vincent

Ling Hong Xie

Xiaojun Liu

Stephen Hubbs

Arthur Nagal

Zhe-Quing Wang

Yawei Shi

Suresh Babu

Andrew Y Thurkauf

Bingsong Han

Jian Lin

He Zhao

John M Peterson

Yang Gao

Dario Doller

Wallace C Pringle

James G Tarrant

Suoming Zhang

Xiao Shu He

Madhu Mondal

LuYan Zhang

Mary-Margaret E O'Donnell

Zhe-qing Wang

Andrew Staab

Christopher Seekamp

Hongwei Zhang

Yuwen Xu

Sonia Rodriguez Rodriguez

Shanming Kuang

Vinod Singh

Xie Ling Hong

Goss Stryker Kauffman

Shawn E Schiller

Shawn ER Schiller

Mark J Tebbe

The present disclosure is directed to solid and salt forms of inhibitors of the CBP/p300 family of bromodomains made up of salts and crystalline forms of Formula (I). The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds.

Inhibiting cyclic AMP-responsive element-binding protein (CREB) binding protein (CBP)

The present disclosure provides crystalline solid forms, spray-dried dispersions and pharmaceutical compositions, including solid oral dosage forms, of (S)-1-(5-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7-sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-3-hydroxy-2-phenylpropan-1-one ('Compound 1'), and preparation methods thereof.

Pyruvate kinase R (PKR) activating compositions

The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.

Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile

Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)

This disclosure relates to compositions and methods for inhibiting mutant IDH1, useful in treatment of mIDH1 cancers including AML, as well as mIDH1-positive solid tumors such as glioma.

Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)

The present disclosure reports solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone: 

Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R, R, R, and Rare as described herein.

Tetrahydroquinoline compositions as BET bromodomain inhibitors

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R, R, Rand Rare defined herein.

Benzopiperazine compositions as BET bromodomain inhibitors

Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile

The present disclosure reports solid forms of (4-(2-fluoro-4-(1-methyl-1H- benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone: 

Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone

Tetrahydroquinoline compositions as bet bromodomain inhibitors

Growing community of inventors

Clinton, CT, United States of America

George P Luke